Prevalence of antibodies against Kaposi's sarcoma associated herpes virus (KSHV) complement inhibitory protein (KCP) in KSHV-related diseases and their correlation with clinical parameters

Vaccine

Volumn 29, Issue 6, 2011, Pages 1129-1134

  Okroj, Marcin ^a   Tedeschi, Rosamaria ^b   Mancuso, Roberta ^c   Brambilla, Lucia ^d   Tourlaki, Athanasia ^d   Dillner, Joakim ^a,e   Blom, Anna M ^a  

^a LUND UNIVERSITY   (Sweden)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antibody; Cancer; Complement; KSHV

Indexed keywords

ANTIBODY; KAPOSI SARCOMA ASSOCIATED HERPES VIRUS COMPLEMENT CONTROL PROTEIN; KAPOSI SARCOMA ASSOCIATED HERPES VIRUS COMPLEMENT CONTROL PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BODY FLUID; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; VIRUS INACTIVATION; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; FEMALE; HERPESVIRUS 8, HUMAN; HUMANS; ITALY; MALE; MIDDLE AGED; SARCOMA, KAPOSI; SEROEPIDEMIOLOGIC STUDIES; SWEDEN; VIRAL LOAD; VIRAL PROTEINS;

EID: 78751567997     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.070     Document Type: Article

References (16)

1. Spiller O.B., Robinson M., O'Donnell E., Milligan S., Morgan B.P., Davison A.J., et al. Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J Virol 2003, 77(1):592-599.
2. Mark L., Spiller O.B., Villoutreix B.O., Blom A.M. Kaposi's sarcoma-associated herpes virus complement control protein: KCP-complement inhibition and more. Mol Immunol 2007, 44(1-3):11-22.
3. Okroj M., Brad Spiller O., Korodi Z., Tedeschi R., Dillner J., Blom A.M. Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals. Vaccine 2007, 25(48):8102-8109.
4. Figueira-Silva C.M., Pereira F.E. Prevalence of Epstein-Barr virus antibodies in healthy children and adolescents in Vitoria, State of Espirito Santo, Brazil. Revista da Sociedade Brasileira de Medicina Tropical 2004, 37(5):409-412.
5. Tornesello M.L., Biryahwaho B., Downing R., Hatzakis A., Alessi E., Cusini M., et al. Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era. Virology 2010, 398(2):280-289.
6. Mancuso R., Biffi R., Valli M., Bellinvia M., Athanasia T., Ferrucci S., et al. HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma. J Med Virol 2008, 80(12):2153-2160.
7. Tedeschi R., Bidoli E., Agren A., Hallmans G., Wadell G., De Paoli P., et al. Epidemiology of Kaposi's Sarcoma herpesvirus (HHV8) in Vasterbotten County, Sweden. J Med Virol 2006, 78(3):372-378.
8. Hjalgrim H., Melbye M., Pukkala E., Langmark F., Frisch M., Dictor M., et al. Epidemiology of Kaposi's sarcoma in the Nordic countries before the AIDS epidemic. Br J Cancer 1996, 74(9):1499-1502.
9. Simonelli C., Tedeschi R., Gloghini A., Talamini R., Bortolin M.T., Berretta M., et al. Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. J Med Virol 2009, 81(5):888-896.
10. Spiller B.O., Blackbourn D., Mark L., Proctor D., Blom A.M. Functional activity of the complement regulator encoded by Kaposis's sarcoma associated herpesvirus. J Biol Chem 2003, 278:9283-9289.
11. Di Lorenzo G. Update on classic Kaposi sarcoma therapy: new look at an old disease. Crit Rev Oncol Hematol 2008, 68(3):242-249.
12. Ramos-da-Silva S., Elgui-de-Oliveira D., Borges L., Bacchi C.E., et al. Kaposi's sarcoma-associated herpesvirus infection and Kaposi's sarcoma in Brazil. Braz J Med Biol Res/Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica 2006, 39(5):573-580.
13. Kanno T., Sato Y., Nakamura T., Sakamoto K., Sata T., Katano H. Genotypic and clinicopathological characterization of Kaposi's sarcoma-associated herpesvirus infection in Japan. J Med Virol 2010, 82(3):400-406.
14. Orenstein J.M. Ultrastructure of Kaposi sarcoma. Ultrastruct Pathol 2008, 32(5):211-220.
15. Spiller O.B., Mark L., Blue C.E., Proctor D.G., Aitken J.A., Blom A.M., et al. Dissecting the regions of virion-associated Kaposi's sarcoma-associated herpesvirus complement control protein required for complement regulation and cell binding. J Virol 2006, 80(8):4068-4078.
16. Brambilla L., Boneschi V., Taglioni M., Ferrucci S. Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices. Eur J Dermatol 2003, 13(1):83-86.